CN107250154A - 包含缺乏糖基化信号的经修饰的噬菌体g3p氨基酸序列的多肽 - Google Patents

包含缺乏糖基化信号的经修饰的噬菌体g3p氨基酸序列的多肽 Download PDF

Info

Publication number
CN107250154A
CN107250154A CN201580065696.9A CN201580065696A CN107250154A CN 107250154 A CN107250154 A CN 107250154A CN 201580065696 A CN201580065696 A CN 201580065696A CN 107250154 A CN107250154 A CN 107250154A
Authority
CN
China
Prior art keywords
seq
amino acid
polypeptide
amino acids
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201580065696.9A
Other languages
English (en)
Chinese (zh)
Inventor
R.克里什南
E.阿斯普
M.普罗希茨基
R.费希尔
F.J.卡尔
R.G.E.霍尔盖特
T.D.琼斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Clara Biosciences Ltd By Share Ltd
Original Assignee
Clara Biosciences Ltd By Share Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Clara Biosciences Ltd By Share Ltd filed Critical Clara Biosciences Ltd By Share Ltd
Publication of CN107250154A publication Critical patent/CN107250154A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1716—Amyloid plaque core protein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/14011—Details ssDNA Bacteriophages
    • C12N2795/14022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Zoology (AREA)
  • Psychology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN201580065696.9A 2014-12-03 2015-12-02 包含缺乏糖基化信号的经修饰的噬菌体g3p氨基酸序列的多肽 Pending CN107250154A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462087052P 2014-12-03 2014-12-03
US62/087,052 2014-12-03
PCT/US2015/063476 WO2016090022A1 (en) 2014-12-03 2015-12-02 Polypeptides comprising a modified bacteriophage g3p amino acid sequence lacking a gylcosylation signal

Publications (1)

Publication Number Publication Date
CN107250154A true CN107250154A (zh) 2017-10-13

Family

ID=55273507

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201580065696.9A Pending CN107250154A (zh) 2014-12-03 2015-12-02 包含缺乏糖基化信号的经修饰的噬菌体g3p氨基酸序列的多肽

Country Status (20)

Country Link
US (2) US10722551B2 (enExample)
EP (1) EP3227313B1 (enExample)
JP (2) JP6730988B2 (enExample)
KR (1) KR20170085132A (enExample)
CN (1) CN107250154A (enExample)
AR (1) AR102890A1 (enExample)
AU (1) AU2015358504A1 (enExample)
BR (1) BR112017011530A2 (enExample)
CA (1) CA2969128A1 (enExample)
DK (1) DK3227313T3 (enExample)
EA (1) EA201791212A1 (enExample)
ES (1) ES2910017T3 (enExample)
IL (1) IL252426A0 (enExample)
MX (1) MX2017007059A (enExample)
PH (1) PH12017501004A1 (enExample)
PL (1) PL3227313T3 (enExample)
PT (1) PT3227313T (enExample)
SG (1) SG11201704427YA (enExample)
TW (1) TW201632542A (enExample)
WO (1) WO2016090022A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112672755A (zh) * 2018-06-15 2021-04-16 普罗克拉拉生物科学股份有限公司 通用淀粉样蛋白相互作用基序(gaim)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2785364B1 (en) 2011-11-29 2019-01-09 Proclara Biosciences, Inc. Use of p3 of bacteriophage as amyloid binding agents
MX358755B (es) 2012-10-02 2018-09-03 Proclara Biosciences Inc Uso del p3 de proteinas de fusion de bacteriofago como agentes de union amiloides.
US9988444B2 (en) 2013-05-28 2018-06-05 Proclara Biosciences, Inc. Polypeptides comprising a modified bacteriophage g3p amino acid sequence with reduced immunogenicity
SG11201704427YA (en) 2014-12-03 2017-06-29 Proclara Biosciences Inc Polypeptides comprising a modified bacteriophage g3p amino acid sequence lacking a gylcosylation signal
KR20250110352A (ko) 2022-12-02 2025-07-18 알제온, 인크. 트라미프로세이트를 이용하여 신경퇴행성 장애를 치료하는 방법

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014055515A1 (en) * 2012-10-02 2014-04-10 Neurophage Pharmaceuticals, Inc. Use of p3 of bacteriophage fusion proteins as amyloid binding agents
CN104093414A (zh) * 2011-11-29 2014-10-08 神经噬菌体制药股份有限公司 噬菌体的p3作为淀粉样蛋白结合剂的用途
CN105473153A (zh) * 2013-05-28 2016-04-06 神经噬菌体制药股份有限公司 包含具有减小的免疫原性的经修饰的噬菌体g3p氨基酸序列的多肽

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3941763A (en) 1975-03-28 1976-03-02 American Home Products Corporation PGlu-D-Met-Trp-Ser-Tyr-D-Ala-Leu-Arg-Pro-Gly-NH2 and intermediates
US4215051A (en) 1979-08-29 1980-07-29 Standard Oil Company (Indiana) Formation, purification and recovery of phthalic anhydride
EP0154316B1 (en) 1984-03-06 1989-09-13 Takeda Chemical Industries, Ltd. Chemically modified lymphokine and production thereof
EP0401384B1 (en) 1988-12-22 1996-03-13 Kirin-Amgen, Inc. Chemically modified granulocyte colony stimulating factor
DE10399023I2 (de) 1989-09-12 2006-11-23 Ahp Mfg B V TFN-bindende Proteine
US6552170B1 (en) 1990-04-06 2003-04-22 Amgen Inc. PEGylation reagents and compounds formed therewith
US5252714A (en) 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
ES2199935T3 (es) 1991-03-15 2004-03-01 Amgen Inc. Pegilacion de polipeptidos.
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
WO1993024135A1 (en) 1992-05-26 1993-12-09 Immunex Corporation Novel cytokine that binds cd30
ES2258817T3 (es) 1997-05-21 2006-09-01 Biovation Limited Metodo para la produccion de proteinas no inmunogenas.
ATE352559T1 (de) 1998-12-08 2007-02-15 Biovation Ltd Verfahren zur verminderung der immunogenität von proteinen
US20020052311A1 (en) 1999-09-03 2002-05-02 Beka Solomon Methods and compostions for the treatment and/or diagnosis of neurological diseases and disorders
US8022270B2 (en) 2000-07-31 2011-09-20 Biolex Therapeutics, Inc. Expression of biologically active polypeptides in duckweed
AU2002233340B2 (en) 2001-02-19 2008-05-22 Merck Patent Gmbh Artificial fusion proteins with reduced immunogenicity
KR20030082962A (ko) 2001-03-08 2003-10-23 메르크 파텐트 게엠베하 감소된 면역원성을 갖는 개질된과립구대식세포집락자극인자(ｇｍ-ｃｓｆ)
DE10238846A1 (de) 2002-08-20 2004-03-04 Nemod Immuntherapie Ag Aktive Fusionsproteine und Verfahren zu ihrer Herstellung
JP5096169B2 (ja) 2005-02-01 2012-12-12 ラモット・アット・テルアビブ・ユニバーシティ アミロイド沈着に付随する炎症および活性化されたマイクログリアにかかわる脳の炎症の処置法
AU2007214399A1 (en) 2006-02-15 2007-08-23 Ramot At Tel-Aviv University Filamentous bacteriophage displaying protein as a binder of antibodies and immunocomplexes for delivery to the brain
WO2007094003A2 (en) 2006-02-15 2007-08-23 Ramot At Tel Aviv University Ltd. Viral display vehicles for treating multiple sclerosis
WO2007109733A2 (en) 2006-03-21 2007-09-27 The Johns Hopkins University Diagnostic and prognostic markers and treatment strategies for multiple sclerosis
US20090105090A1 (en) 2006-04-06 2009-04-23 Fumiaki Uchiyama Phage Display By Novel Filamentous Bacteriophage
CN101553567A (zh) 2006-07-21 2009-10-07 台拉维夫大学拉莫特 抑制或治疗与细胞内形成蛋白纤维状内含体或聚集体相关的疾病的方法
KR101485202B1 (ko) 2006-10-11 2015-01-22 안티토페 리미티드 Ｔ 세포 에피토프 데이터베이스들
WO2009143470A1 (en) 2008-05-22 2009-11-26 Ramot At Tel Aviv University Ltd. Method for treating disease characterized by plaque
AU2009316326A1 (en) 2008-11-24 2010-05-27 Ramot At Tel-Aviv University Ltd. Method for treating Parkinson' s disease using filamentous bacteriophage
WO2011084714A2 (en) 2009-12-17 2011-07-14 Biogen Idec Ma Inc. STABILIZED ANTI-TNF-ALPHA scFv MOLECULES OR ANTI-TWEAK scFv MOLECULES AND USES THEREOF
JP2014509514A (ja) 2011-03-11 2014-04-21 ラモット アット テルアヴィブ ユニヴァーシティ リミテッド 神経変性タウオパシーを治療するための方法
SG11201704427YA (en) 2014-12-03 2017-06-29 Proclara Biosciences Inc Polypeptides comprising a modified bacteriophage g3p amino acid sequence lacking a gylcosylation signal

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104093414A (zh) * 2011-11-29 2014-10-08 神经噬菌体制药股份有限公司 噬菌体的p3作为淀粉样蛋白结合剂的用途
WO2014055515A1 (en) * 2012-10-02 2014-04-10 Neurophage Pharmaceuticals, Inc. Use of p3 of bacteriophage fusion proteins as amyloid binding agents
CN105473153A (zh) * 2013-05-28 2016-04-06 神经噬菌体制药股份有限公司 包含具有减小的免疫原性的经修饰的噬菌体g3p氨基酸序列的多肽

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ELIZABETH M. MUIR等: "Modification of N-glycosylation sites allows secretion of bacterial chondroitinase ABC from mammalian cells", 《JOURNAL OF BIOTECHNOLOGY》 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112672755A (zh) * 2018-06-15 2021-04-16 普罗克拉拉生物科学股份有限公司 通用淀粉样蛋白相互作用基序(gaim)

Also Published As

Publication number Publication date
AR102890A1 (es) 2017-03-29
PH12017501004A1 (en) 2017-12-18
JP2020073610A (ja) 2020-05-14
ES2910017T3 (es) 2022-05-11
US20180207231A1 (en) 2018-07-26
EP3227313B1 (en) 2022-02-09
JP6730988B2 (ja) 2020-07-29
US11723951B2 (en) 2023-08-15
DK3227313T3 (da) 2022-04-19
BR112017011530A2 (pt) 2018-03-13
WO2016090022A1 (en) 2016-06-09
PL3227313T3 (pl) 2022-05-09
EA201791212A1 (ru) 2018-01-31
AU2015358504A1 (en) 2017-06-29
US20210015895A1 (en) 2021-01-21
AU2015358504A8 (en) 2017-07-13
IL252426A0 (en) 2017-07-31
CA2969128A1 (en) 2016-06-09
SG11201704427YA (en) 2017-06-29
JP2017538407A (ja) 2017-12-28
TW201632542A (zh) 2016-09-16
KR20170085132A (ko) 2017-07-21
US10722551B2 (en) 2020-07-28
MX2017007059A (es) 2018-05-02
WO2016090022A8 (en) 2017-06-22
WO2016090022A9 (en) 2016-08-25
PT3227313T (pt) 2022-04-12
EP3227313A1 (en) 2017-10-11

Similar Documents

Publication Publication Date Title
US11723951B2 (en) Polypeptides comprising a modified bacteriophage G3P amino acid sequence lacking a glycosylation signal
US9988444B2 (en) Polypeptides comprising a modified bacteriophage g3p amino acid sequence with reduced immunogenicity
CN111225923B (zh) 结合活性α突触核蛋白的抗体
CN104870008B (zh) 噬菌体的p3融合蛋白作为淀粉样蛋白结合剂的用途
EP4083212A1 (en) Mutant rsv f protein and use thereof
AU2019287623B2 (en) General amyloid interaction motif (GAIM)
HK1249520B (en) Polypeptides comprising a modified bacteriophage g3p amino acid sequence lacking a glycosylation signal
CN113164573B (zh) 包含修饰的MHC II类DRα1结构域的重组多肽及其应用方法
JP2023155237A (ja) サイクリン依存性キナーゼ５（ｃｄｋ５）阻害性ペプチド
HK40110180A (en) General amyloid interaction motif (gaim)
JP2022516574A (ja) 新規ペプチドとその使用
HK40081120A (en) Mutant rsv f protein and use thereof
EA046070B1 (ru) Общий амилоид-взаимодействующий мотив (gaim)
HK40049127A (en) General amyloid interaction motif (gaim)
HK40049127B (en) General amyloid interaction motif (gaim)

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20171013

WD01 Invention patent application deemed withdrawn after publication